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Amyotrophic lateral sclerosis is a neurodegenerative disease of motor neurons with a median survival of 2 years. Most patients
have no family history of amyotrophic lateral sclerosis, but current understanding of such diseases suggests there should be an
increased risk to relatives. Furthermore, it is a common question to be asked by patients and relatives in clinic. We therefore set
out to determine the risk of amyotrophic lateral sclerosis to ﬁrst degree relatives of patients with sporadic amyotrophic lateral
sclerosis attending a specialist clinic. Case records of patients with sporadic amyotrophic lateral sclerosis seen at a tertiary
referral centre over a 16-year period were reviewed, and pedigree structures extracted. All individuals who had originally
presented with sporadic amyotrophic lateral sclerosis, but who subsequently had an affected ﬁrst degree relative, were identi-
ﬁed. Calculations were age-adjusted using clinic population demographics. Probands (n = 1502), full siblings (n = 1622) and full
offspring (n = 1545) were identiﬁed. Eight of the siblings and 18 offspring had developed amyotrophic lateral sclerosis. The
unadjusted risk of amyotrophic lateral sclerosis over the observation period was 0.5% for siblings and 1.0% for offspring. Age
information was available for 476 siblings and 824 offspring. For this subset, the crude incidence of amyotrophic lateral
sclerosis was 0.11% per year (0.05–0.21%) in siblings and 0.11% per year (0.06–0.19%) in offspring, and the clinic
age-adjusted incidence rate was 0.12% per year (0.04–0.21%) in siblings. By age 85, siblings were found to have an 8-fold
increased risk of amyotrophic lateral sclerosis, in comparison to the background population. In practice, this means the risk of
remaining unaffected by age 85 dropped from 99.7% to 97.6%. Relatives of people with sporadic amyotrophic lateral sclerosis
have a small but deﬁnite increased risk of being affected.
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Introduction
Amyotrophic lateral sclerosis (ALS), shows complex inheritance
(Al-Chalabi et al., 2010). Although 5% of cases have a clear
family history of ALS in ﬁrst degree relatives, a family history in
more distant relatives or of diseases suggestive of ALS or fronto-
temporal dementia also occurs in some (Fallis and Hardiman,
2009; Byrne and Hardiman 2010). Founder studies show that
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common genetic cause for ALS because of a common ancestor
(Al-Chalabi et al., 1998). Given that many people do not know
their family history beyond ﬁrst degree relatives and that causes of
death are even less likely to be known, it is difﬁcult to deﬁne
exactly what is meant by sporadic ALS.
A recent population-based study has estimated the increased risk
of ALS to ﬁrst degree relatives as between 9 and 17 times, but did
not distinguish between those with and without a family history
(Fang et al., 2009). Furthermore, a specialist ALS clinic population
is typically biased compared to a population-based sample in con-
taining younger, motivated patients and those with atypical forms
of ALS (Armon et al., 2002). It is common to be asked in such a
clinic whether there is an increased risk to relatives. We therefore
sought a practical estimate of the risk in a clinic setting to relatives
of individuals with sporadic ALS.
Materials and methods
Inclusion criteria
Ethically approved, written informed consent was obtained from all
patients. The diagnosis of ALS was made by two neurologists after
exclusion of other conditions. Patients with a diagnosis of ALS, ﬂail
arm variant of ALS, primary lateral sclerosis or progressive muscular
atrophy were included.
Data collection
Detailed pedigree information was reviewed for every patient seen
between 1994 and 2009 in a tertiary referral clinic with a catchment
population of 3 million. An in-depth search was undertaken to iden-
tify any family member who had also been seen in the clinic. Patients
with a family history were excluded. Only relatives alive at the time
the proband was ﬁrst seen were included in the analysis. Any patient
seen in the clinic who was the second person in their family to be
diagnosed was identiﬁed and the initial relative ﬂagged as reclassiﬁed
from sporadic to familial ALS.
Statistical methods
Demographic characteristics were compared using t-tests. Age of
onset data were transformed to normal before analysis. The Fisher’s
exact test was used to test the independence of gender and having an
affected relative. The unadjusted risk was calculated as the ratio be-
tween observed cases in siblings and offspring and the total number of
siblings and offspring at risk. For the subset of siblings whose ages
were known, age-adjusted incidence rates were calculated by adjust-
ing to the clinic population demographics.
The risk of ALS to a sibling of a proband was compared to that of
the background population from an ALS population register drawn
from the area surrounding the clinic and analysed with Kaplan–
Meier product limit distribution over the 16-year observation period
of the study. All P-values were two-sided. Calculations were per-
formed in SPSS (version 16.0, SPSS Inc.).
Results
Patients with ALS (n = 1502) seen between 1994 and 2009 met
the inclusion criteria. They had 1622 siblings and 1545 offspring
(Table 1).
There was no difference between the characteristics of probands
with unaffected and subsequently affected ﬁrst degree relatives
for gender (Fisher’s exact test, P = 0.68) and average age of
onset (two-sided t-test, P = 0.37). Eight new cases of ALS were
identiﬁed in siblings and 18 in offspring of probands, giving an
unadjusted risk of ALS of 0.5% in siblings and 1.0% in offspring.
Age information was available for 478 siblings and 824 off-
spring. For this subset the overall crude incidence was 0.11%
per year (0.05–0.21%) in siblings and 0.11% per year (0.06–
0.19%) in offspring.
Age-adjustment using the clinic population gave an incidence
rate for siblings of 0.12% per year (0.04–0.21%). By age 85,
siblings had an 8-fold increased risk of ALS compared with the
background population, with a risk of 2.4% (0.6–4.2%; Fig. 1).
For offspring, because 90% of the offspring did not reach the
median age of ALS diagnosis by the end of the study
period, an accurate age-adjusted incidence rate was not possible.
Where age was available, of 607 offspring aged below
50 years, seven were subsequently diagnosed with ALS and of
68 offspring aged greater than 56 years, 11 were subsequently
diagnosed with ALS. There was no difference between the aver-
age age of disease onset of siblings and offspring (two-sided t-
test, P = 0.31).
Table 1 Mean age at onset in years for probands and relatives
Males (n) Females (n) Total (n)
Probands 56.7 (939) 58.9 (563) 57.6 (1502)
Siblings 65.5 (653) 68.2 (969) 66.6 (1622)
Offspring 41.3 (922) 38.9 (623) 38.1 (1545)
Probands with relatives remaining unaffected 56.7 (924) 58.9 (552) 57.5 (1476)
Probands with relatives subsequently diagnosed 58.2 (15) 62.0 (11) 60.5 (26)
Probands with siblings subsequently diagnosed 57.5 (6) 42.0 (2) 53.6 (8)
Probands with offspring subsequently diagnosed 64.3 (9) 63.0 (8) 63.8 (17)
Affected siblings 57.0 (2) 63.8 (6) 62.1 (8)
Affected offspring 57.8 (10) 50.5 (8) 54.5 (18)
A daughter had a subsequently affected mother, and a father had subsequently affected monozygous twins, both of which affect counts in the table.
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Over 16 years we found that 0.5% of siblings and 1% of off-
spring of patients with apparently sporadic ALS subsequently de-
veloped ALS. The crude risk of a diagnosis of ALS per year for ﬁrst
degree relatives was about 0.1%. These results highlight a prac-
tical dilemma and require careful interpretation. This could be re-
garded as a misclassiﬁcation study, estimating the rate at which
familial ALS is misdiagnosed as sporadic ALS. However, like all
complex diseases, ALS also demonstrates familial clustering with-
out necessarily showing Mendelian inheritance (Fang et al., 2009),
as well as presenting an increased risk to relatives of several neu-
rodegenerative diseases (Fallis and Hardiman, 2009). The distinc-
tion between familial and sporadic ALS is therefore to some extent
artiﬁcial, although convenient.
The age adjusted risk of a subsequent diagnosis of ALS in sib-
lings was estimable at 0.12% per year (0.04–0.21%). Comparison
with the population risk of ALS showed that by age 85, siblings
had an 8-fold increased risk of ALS. This should however be put in
context. The actual risk was just 2.4% (0.6–4.2%), which means
that the risk of remaining unaffected by age 85 had dropped from
99.7% to 97.6% (Fig. 1). In other words, siblings are still over-
whelmingly likely to die of heart disease, stroke or cancer, rather
than ALS. We could not accurately estimate the risk to offspring
because the numbers at risk in the older age groups are small,
there is considerable censoring of data and a small denominator.
This study should not be regarded as a population estimate of
the risk to relatives of those with ALS. We have deliberately stu-
died a clinic population because this is biased and yet is the con-
text in which the clinical (as opposed to research) question is
asked. The age of onset, diagnostic delay, distribution of bulbar
onset and median survival of our clinic population is similar to that
of other published clinic populations from tertiary referral centres
(Thijs et al., 2000; Magnus et al., 2002, Czaplinski et al., 2006,
Talman et al., 2009), but is likely to be different from that of a
general neurology clinic or healthcare systems that do not provide
free universal access. Nevertheless, the conclusion that there is a
small but deﬁnite increased risk to ﬁrst degree relatives is likely to
be valid.
Complex diseases like ALS, which show familial clustering and her-
itability, can be explained genetically with the Liability Threshold
Model, in which multiple risk factors lead to a normal distribution
of disease risk in the population, but for which disease only occurs
once a threshold of risk burden is reached (Falconer, 1965). Under
this model, one expects that ﬁrst degree relatives have an in-
creased risk that is approximately the square root of the popula-
tion risk (Edwards, 1960). For ALS, the cumulative lifetime risk by
age 85 is about 1 in 338 in our local population (Johnston et al.,
2006), giving an expected risk to ﬁrst degree relatives of 5.4%,
which is of the same order of magnitude as our observed value.
A weakness of this study is that we relied on affected relatives
coming to the same clinic as the proband, since we did not ac-
tively follow-up every family of those with sporadic ALS. This can
be expected to lead to under-ascertainment. In addition, the
age-adjustment was performed only on the proportion of siblings
with age information. Affected relatives are more likely to have
age information than the unaffected, which represents a further
source of bias.
Non-paternity might be expected to confound our ﬁndings.
Estimates of non-paternity rates vary widely, but a rate of about
1.6% for the UK is reasonable (Anderson, 2006), so about 24 of
the probands in our sample might be children with different bio-
logical fathers from the expected. The risk of familial ALS in the
population is 5–10% of the lifetime risk of ALS as a whole (Byrne
et al., 2011). A liberal estimate is therefore 24  10%  1/338, so
the probability of this affecting our study is 51%.
This study differs from previous Swedish work estimating the
risk to relatives (Fang et al., 2009) in two important respects.
First, the Swedish study was population based, whereas this
study is clinic based. Second, the Swedish study made no distinc-
tion between those with familial and sporadic ALS, whereas we
have speciﬁcally examined the population with sporadic ALS.
We have shown a small but deﬁnite increased risk to relatives of
patients with sporadic ALS seen in a tertiary referral clinic in the
UK. The increase in risk should be seen in the context of other
causes of death and could be regarded as a measure of uncer-
tainty in family histories obtained in a specialist centre.
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Figure 1 Proportion of siblings remaining unaffected in the
clinic population compared with the background population risk.
Siblings represented by black line with 95% conﬁdence limits as
thinner dashed lines. Risk to local population shown by upper
grey line. Note the Y axis starts at 0.95, not zero.
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